Volume 29, Number 11—November 2023
Research
Systematic Review and Meta-analysis of Deaths Attributable to Antimicrobial Resistance, Latin America
Table
Type of resistance | OR (95% CI) | I2 |
---|---|---|
Carbapenem-resistance | 2.86 (2.07–3.95) | 61% |
Extended-spectrum β-lactamase | 1.28 (0.95–1.74) | 38% |
Methicillin-resistance | 1.78 (1.29–2.45) | 63% |
MDRO† | 1.64 (1.16–2.30) | 68% |
Azol-resistant | 1.41 (0.59–3.35) | - |
Vancomycin-resistant | 4.09 (2.40–6.97) | 0% |
Random effect model | 1.86 (1.55–2.23) | 71% |
*MDRO, multidrug-resistant organisms; OR, pooled odds ratio. †Multidrug-resistant organisms include methicillin-resistant Staphylococcus aureus, Vancomycin-resistant Enterococcus spp, extended-spectrum β-lactamase producing Enterobacterales, carbapenem-resistant Enterobacterales (including Klebsiella, Enterobacter, Escherichia coli, Proteus, Serratia), carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Acinetobacter baumannii and azole/echinocandin-resistant Candida spp.
Page created: September 20, 2023
Page updated: October 23, 2023
Page reviewed: October 23, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.